Skip to content
AnalystLens

Charles River Laboratories International Annual Report, Year Ended Dec 26, 2015

Filing Date
Filed February 12, 2016
Period End
December 26, 2015
Security
CRL
One revenue dollarkept$0.11
In the record · 2016–202610-K1110-Q338-K117

CRL filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 117 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Apr ’18Apr ’18
  2. Material agreement8-K · Oct ’19Oct ’19
  3. Leadership change8-K · Mar ’22Mar ’22
  4. Leadership change8-K · May ’26May ’26

Summary

Summary of the 10-K filed February 12, 2016. Cited figures are marked; the original filing is the authoritative source.

Charles River Laboratories International, Inc. ("CRL") describes itself as a full service, early-stage contract research organization (CRO) that provides research models, discovery and safety assessment services, and manufacturing support products and services.

In 2015, total revenue was $1.36 billiona (total revenue $1,363,302 thousand), up from $1.30 billion in 2014, and income from continuing operations before income taxes was $195.4 million. The company has three reporting segments: Research Models and Services (RMS, 34.7% of 2015 revenue), Discovery and Safety Assessment (DSA, 44.9%), and Manufacturing Support (20.4%). Net income attributable to common shareholders was $149.3 million, or $3.13 diluted earnings per share, compared with $126.7 million in 2014.

Growth in 2015 came mainly from DSA, where revenue rose $74.0 millionb, or 13.7%, driven by higher Safety Assessment study volume and the Argenta, BioFocus, ChanTest and Oncotest acquisitions. Manufacturing revenue rose $25.8 million, or 10.2%, on the Celsis and Sunrise acquisitions, while RMS revenue fell $34.2 million, or 6.7%, largely due to foreign exchange. Foreign currency reduced total 2015 revenue by $69.4 million, or 5.3%.

Total debt and capital lease obligations were $863.0 millionc at year-end, and cash and cash equivalents were $117.9 million. Looking ahead, the company agreed on January 6, 2016 to acquire WIL Research for approximately $585.0 million in cash, expected to close early in the second quarter of 2016.

The acquisition is to be financed through an expansion of the credit facility of up to $350.0 milliond and cash on hand. The filing also discloses an IDEXX patent infringement complaint, which the company intends to defend vigorously, and an internal investigation into inaccurate government contract billing, for which a liability of approximately $1.5 million has been recorded.

Key Highlights

  1. Total revenue of $1.36 billion in 2015, up from $1.30 billion in 2014; revenue increased $65.6 million, or 5.1%, despite a $69.4 million foreign currency headwind.
  2. Operating income of $206.4 million and income from continuing operations of $152.0 million in 2015, versus $177.7 million and $129.9 million in 2014.
  3. DSA segment, 44.9% of 2015 revenue, grew 13.7%, driven by Safety Assessment study volume and acquisitions; RMS fell 6.7% and Manufacturing grew 10.2%.
  4. Pending WIL Research acquisition for approximately $585.0 million in cash, with a $17.5 million termination fee payable in specified circumstances and up to $350.0 million of additional debt financing.
  5. Total debt and capital lease obligations of $863.0 million at year-end 2015, with a $1.3 billion credit facility and $69.7 million remaining under the stock repurchase program.
  6. Acquisitions in 2015 included Celsis ($214.5 million purchase price), Oncotest ($36.0 million preliminary) and Sunrise Farms ($9.6 million), which produced a $9.8 million bargain purchase gain.
  7. Pending IDEXX patent infringement complaint filed July 31, 2015; the company intends to defend vigorously and states no estimate of possible loss can be made.

Follow one dollar

Of each $1.00 of revenue in FY2015, Charles River Laboratories International kept $0.11.

  1. Revenue$1.36B100.0%
  2. Cost of revenue−$264.0M19.4%
  3. Gross profit$1.10B80.6%
  4. Operating costs−$892.9M65.5%
  5. Operating income$206.4M15.1%
  6. Interest, other & tax−$57.1M4.2%
  7. Net income$149.3M11.0%
Computed from 10-KFY2015filed February 12, 2016Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Where FY2015 revenue went

$1.36B
  • Other operating costs: $592.5M, 43% of revenue
  • SG&A: $300.4M, 22% of revenue
  • Cost of revenue: $264.0M, 19% of revenue
  • Net income: $149.3M, 11% of revenue
  • Interest, other & tax: $57.1M, 4.2% of revenue

Kept 11% as net incomeNet income $149.3M · 11%

Full revenue history →

Financial Statements

FY2015 against FY2014

Line itemFY2015FY2014Change
Revenue$1.36B$1.30B+5.1%
Cost of Revenue$263.98M$266.42M−0.9%
Gross Profit$1.10B$1.03B+6.6%
SG&A Expenses$300.41M$269.03M+11.7%
Operating Income$206.45M$177.67M+16.2%
Interest Expense$15.07M$11.95M+26.1%
Net Income$149.31M$126.70M+17.8%
EPS (Basic)$3.21$2.72+18.0%
EPS (Diluted)$3.13$2.66+17.7%
Shares Outstanding (Basic)46.50M46.63M−0.3%
Shares Outstanding (Diluted)47.63M47.56M+0.2%

Frequently Asked Questions

  1. How did Charles River's revenue and profitability trend in 2015?

    Total revenue rose to $1,363.3 million from $1,297.7 million, an increase of $65.6 million or 5.1%. Operating income rose to $206.4 million from $177.7 million, and net income attributable to common shareholders rose to $149.3 million from $126.7 million. Diluted EPS from net income was $3.13 versus $2.66 in 2014.

  2. Which business segments drove growth and which declined?

    DSA revenue increased $74.0 million, or 13.7%, to $612.2 million, led by Safety Assessment volume and the Argenta, BioFocus, ChanTest and Oncotest acquisitions. Manufacturing revenue increased $25.8 million, or 10.2%, on Celsis and Sunrise. RMS revenue decreased $34.2 million, or 6.7%, mainly due to foreign exchange, and the filing notes lower research model services revenue and lower research models revenue in Japan.

  3. What is the WIL Research acquisition and how will it be funded?

    On January 6, 2016, the company agreed to acquire WRH, Inc. (WIL Research), a provider of safety assessment and contract development and manufacturing services, for a preliminary purchase price of approximately $585.0 million in cash. The company expects the deal to close early in the second quarter of 2016, subject to regulatory approvals. It will be financed through an expansion of the credit facility and cash, and a termination fee of $17.5 million may be payable if the agreement ends under specified circumstances.

  4. What is the company's debt and liquidity position at year-end 2015?

    Total debt and capital lease obligations were $863.0 million, compared with $772.5 million a year earlier, and cash and cash equivalents were $117.9 million. The company's $1.3 billion credit facility included $446.0 million drawn on the revolver and $390.0 million of term loans. The company stated it was in compliance with all covenants as of December 26, 2015.

  5. What legal matters could affect investors?

    IDEXX Laboratories filed a complaint in July 2015 alleging infringement of three patents related to a dried blood spot sample collection method; the company has moved to dismiss and intends to defend vigorously, and no estimate of possible loss can be made. Separately, an internal investigation found that the RMS business billed the government for some work not performed, and the company has recorded a liability of approximately $1.5 million, while noting additional losses are reasonably possible but cannot yet be estimated.